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Summary
Worldwide shortage of standard brain dead donors (DBD) has revived the use
of kidneys donated after circulatory death (DCD). We reviewed the Belgian
DCD kidney transplant (KT) experience since its reintroduction in 2000. Risk
factors for delayed graft function (DGF) were identified using multivariate
analysis. Five-year patient/graft survival was assessed using Kaplan–Meier
curves. The evolution of the kidney donor type and the impact of DCDs on
the total KT activity in Belgium were compared with the Netherlands. Between
2000 and 2009, 287 DCD KT were performed. Primary nonfunction occurred
in 1% and DGF in 31%. Five-year patient and death-censored graft survival
were 93% and 95%, respectively. In multivariate analysis, cold storage (versus
machine perfusion), cold ischemic time, and histidine-tryptophan-ketoglutarate
solution were independent risk factors for the development of DGF. Despite an
increased number of DCD donations and transplantations, the total number of
deceased KT did not increase significantly. This could suggest a shift from
DBDs to DCDs. To increase KT activity, Belgium should further expand con-
trolled DCD programs while simultaneously improve the identification of all
potential DBDs and avoid their referral for donation as DCDs before brain
death occurs. Furthermore, living donation remains underused.
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Introduction
Organ shortage has urged transplant physicians to
expand the acceptance criteria of deceased donors. The
use of expanded criteria donor (ECD) kidneys and kid-
neys donated after circulatory death (DCD) has
increased significantly. About one-third of deceased kid-
ney transplant activity in the United States is performed
with kidneys from ECDs and DCDs [1]. Although DCD
donation was common practice in the early era of trans-
plantation, the introduction of brain death criteria and
the superior results achieved with organs donated after
brain death (DBD) pushed DCD donation to the back-
ground [2]. DCDs were reported to have considerably
higher incidences of delayed graft function (DGF) and
primary nonfunction (PNF) as compared with DBD kid-
neys (28–88% and 1–18% vs. 13–35% and 1–10%,
respectively) [3,4] and inferior graft outcome. However,
with the successful course of clinical transplantation
activities, the DBD pool rapidly became insufficient to
sustain the increasing demand for kidney grafts. Conse-
quently, DCD kidney programs were established as the
full potential of the DCD pool was estimated larger than
that of the DBD pool and could double or even quadru-
ple the number of deceased donor kidney transplanta-
tions [5]. In addition, some landmark publications at
the turn of the century showed that excellent long-term
graft survival, equivalent to DBD kidneys, could be
achieved with DCD kidneys [6,7]. These early reports
were subsequently confirmed in larger series [3,8,9]. The
excellent results of DCD kidney transplantation com-
bined with the growing organ shortage has led to a
steady increase of DCD kidney transplant activity in
countries with the required legal framework and now
reaches up to 30–40% of deceased donor kidney trans-
plantations in the United Kingdom (UK) and the Neth-
erlands [8,10].
Despite a legal framework allowing maximal efforts to
stimulate organ donation and transplantation (opting-
out, legality of DBD, DCD, and living donation [11]) and
one of the highest deceased donor rates per capita world-
wide, Belgium is still confronted with a renal graft short-
age. Less than 50% of waitlisted patients are transplanted
yearly [10]. Therefore, in an attempt to increase the num-
ber of kidney transplants, DCD kidney transplant pro-
grams were reintroduced in Belgium at the turn of the
century.
In this report, we review the 10-year Belgian DCD kid-
ney transplant experience with particular emphasis on (i)
results, (ii) risk factors for DGF, (iii) the evolution of the
different types of kidney donation, and (iv) the evolution
of the overall kidney transplant activity.
Patients and methods
Study population
Donor and recipient data from all DCD kidney trans-
plants performed in Belgium between January 1, 2000
and December 31, 2009 were retrieved from the registry
of the international organ-exchange organization Euro-
transplant [10] and the seven Belgian kidney transplant
centers, represented by the Kidney-Pancreas Committee.
Recipients younger than 18 years of age at the time of
transplantation were excluded, as were combined trans-
plantations.
Delayed graft function was defined as the need for dial-
ysis in the first week after transplantation, preceding
return of graft function. PNF was defined as a graft that
never regained function. Warm ischemic time was defined
as the time from withdrawal of life support to start of
cold perfusion, acirculatory time as the time from cardio-
circulatory arrest until start of cold perfusion, cold ische-
mic time as the time from start cold perfusion to start of
the vascular anastomoses, and anastomotic time as the
time from start of the vascular anastomoses until reperfu-
sion of the graft. HLA mismatching between donor and
recipient was categorized according to differences at the
HLA-A, HLA-B, and HLA-DR loci; with 0–1 of six possi-
ble mismatches categorized as ‘level 1’, 2–4 mismatches as
‘level 2’, and 5–6 as ‘level 3’. Graft survival was defined as
the time from transplantation to return to dialysis, graft
nephrectomy or to patient death with a functioning graft,
whichever came first. Early acute rejection was defined as
the treatment of biopsy-proven rejection within the first
3 months after transplantation.
The evolution of kidney donation and transplantation
rates in Belgium and the Netherlands, both Eurotrans-
plant countries, was studied by comparing activity in
three chronological eras (1995–1999, 2000–2005, and
2006–2010). Kidney donation and kidney-only transplan-
tation rates were obtained from the Eurotransplant regis-
try. Rates were adjusted for the number of inhabitants
using Eurostat population data [12].
Statistical analysis
Continuous variables are expressed as median (inter-quar-
tile range), categorical variables as number (and percent-
age). Comparisons of continuous variables between
groups were performed using Mann–Whitney U-test or
Kruskall–Wallis test. Comparisons of categorical variables
were performed using Chi-squared or Fisher exact test.
Univariate and multivariate logistic regression models
were constructed to find independent risk factors of DGF.
The multivariate model was constructed by backward
Kidney transplantation of grafts donated after circulatory death in Belgium Jochmans et al.
ª 2012 The Authors
858 Transplant International ª 2012 European Society for Organ Transplantation 25 (2012) 857–866
stepwise regression using covariates with a univariate
P-value <0.15. As only three cases of PNF occurred, no
further analyses on PNF were performed. Kaplan–Meier
curves were used to assess patient and graft survival. The
effect of DCD type (controlled versus uncontrolled DCD)
on 5-year patient and graft survival was assessed using
log-rank testing. Because of a limited number of deaths
and graft losses (n = 25 and n = 18, respectively), no Cox
regressions were performed. P-values <0.05 were consid-
ered to indicate statistical significance. All data analyses
were performed in SPSS-16.
Results
Study population
A total of 287 DCD kidney transplants were performed in
Belgium during the 10-year study period (i.e., 7.4% of all
deceased donor kidney transplants). In the same period,
175 DCD procedures were performed (i.e., 7.8% of all
deceased donor procedures). Donor and recipient charac-
teristics are shown in Table 1. During the study period,
pediatric donors were not considered for DCD donation
and generally the upper age limit for DCD donation was
considered to be 60 years. DCD kidneys were allocated
following standard Eurotransplant allocation rules and
were transplanted for all common transplant indications
(Table 2). Ninety-one percent of DCD kidneys were pro-
cured in Belgium, whereas 9% were imported. Ninety-
three percent of kidneys were recovered from controlled
Maastricht Category III donors leading to relatively short
warm ischemic and acirculatory times, 7% were recovered
from uncontrolled Maastricht Category II donors
(Table 1) [13]. Prior to 1998, duration of the ‘no-touch’
period varied from 2 to 10 min, depending on center
practice. However, since the US recommendation of the
Institute of Medicine, a 5-min period became standard in
most centers [14].
Histidine-tryptophan-ketoglutarate (HTK) solution was
used as flush solution in 83% of donors, and University
of Wisconsin solution (UW) in 16%. Kidneys were pre-
served either by cold storage (47%) or by machine perfu-
sion (53%), depending on the preference of the recipient
center. Of machine-perfused kidneys, 82% were placed on
the machine directly after procurement in the donor cen-
ter (immediate perfusion). In 18%, machine perfusion
was started after an initial period of cold storage (delayed
perfusion). All kidneys preserved on the machine were
perfused with Belzer’s machine perfusion solution, avail-
able as KPS-1 (Organ Recovery Systems, Itasca, IL, USA)
[15]. Between 2000 and 2003, the RM3 machine (Waters
Medical Systems, Rochester, MN, USA) was used. There-
after, kidneys were perfused on LifePort Kidney Trans-
porter machines (Organ Recovery Systems). Eighty-nine
Table 1. Characteristics of donors and recipients of kidneys donated
after circulatory death in Belgium between 2000 and 2009.
Variable
Donor characteristics (n = 179)




Terminal serum creatinine value (mg/dl)*, 0.70 (0.56–0.91)
History of arterial hypertension, n (%)† 27 (17)
Donor type, n (%)‡
Uncontrolled DCD (Category I + II) 11 (6)
Controlled DCD (Category III + IV) 168 (94)
Warm ischemic time (min)* 20 (15–29)
Acirculatory time (min)* 10 (8–14)
Flush solution, n (%)
Histidine-tryptophan-ketoglutarate 149 (83%)
University of Wisconsin solution 28 (16%)
Others 2 (1%)
Process (n = 287)
Preservation method, n (%)
Machine perfusion 152 (53)
Cold storage 135 (47)
Cold ischemic time (h)* 16 (12–19)
Anastomotic time (min)* 31 (11–71)
Recipient characteristics (n = 287)




Duration dialysis therapy (months)* 29 (17–48)
Previous transplants, n (%)
First transplant 261 (91)
Retransplant 26 (9)
Panel reactive antibodies, n (%)
n = 0–5% 257 (89.5)
n = 6–84% 29 (10.1)
n ‡ 85% 1 (0.3)
HLA mismatches, n (%)
Level 1 32 (11)
Level 2 252 (88)
Level 3 3 (1)
Donor type, n (%)
Uncontrolled DCD (Category I + II) 20 (7)
Controlled DCD (Category III + IV) 267 (93)
Immunosuppression, n (%)†
Induction therapy 207 (72.6)
Anti-thymocyte globulin 37 (32.4)
Interleukin 2 receptor antagonist 139 (67.1)
Calcineurin inhibitor 285 (100)
Delayed 35 (12.3)
Mycophenolate mofetil 265 (93)
Corticosteroids 285 (100)
Outcome data, n (%) (n = 287)
Primary nonfunction 3 (1)
Delayed graft function 89 (31)
Immediate function 195 (68)
Acute rejection† 50 (17.5)
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percent of machine-preserved kidneys were perfused on
LifePort machines.
Recipient immunosuppression varied according to cen-
ter specific practice (Table 1): 72.6% of recipients
received induction therapy, the introduction of calcineu-
rin inhibitors was delayed in only 12.3% of cases. Mainte-
nance immunosuppression consisted of calcineurin
inhibitors (100%), mycophenolate mofetil (93%), and
corticosteroids (100%).
Recipients were followed for a median of 34 months
(18–46), during which time PNF developed in 1% and
DGF in 31% of cases. Machine-perfused kidneys experi-
enced a numerically 9% lower DGF rate compared with
cold stored kidneys (27% and 36%, respectively,
P = 0.07). The DGF incidence of kidneys with delayed
versus immediate machine perfusion was similar (33%
and 26%, respectively, P = 0.48). DGF rate in uncon-
trolled DCDs was higher compared with controlled DCDs
(65.0% vs. 28.5% respectively; P = 0.001); however, PNF
rates were similar (0% vs. 1%, respectively; P = 0.63).
DCD kidney transplantation resulted in excellent 5-year
patient and death-censored graft survival (93% and 95%,
respectively) (Table 1, Fig. 1). Patient and death-censored
graft survival of uncontrolled DCDs were similar to con-
trolled DCDs (85% vs. 93%; P = 0.22 and 94% vs. 95%;
P = 0.98, respectively).
Risk factors for the development of DGF
Results from univariate and multivariate regression analy-
sis are shown in Table 3. After correction for donor and
recipient variables, cold storage (versus machine perfu-
sion), cold ischemic time, and flush with HTK were inde-
pendent risk factors for DGF. The type of DCD donor
(uncontrolled or controlled) was not an independent risk
factor in multivariate analysis, nor was warm ischemic
time or acirculatory time.
Evolution of kidney donation and transplantation rates
in Belgium since 1995
Between 1995 and 2010, the majority of effective Belgian
kidney donors were deceased donors [20.6 per million
population (pmp) (19.0–22.4)], mainly DBDs [19.4 pmp
(18.3–20.9)] with a small portion of DCDs [0.4 pmp
(0.2–2.8)]. Living donation [2.2 pmp (1.5–3.8)] increased
the total number of effective kidney donors in Belgium to
23.0 pmp (21.1–26.0) (Fig. 2a). Kidney transplantation
rates showed a similar distribution: a majority of deceased
donors [37.9 pmp (31.9–38.8)], mainly DBDs [33.5 pmp
(30.3–37.1)] and a few DCDs [0.7 pmp (0.3–4.8)]. Living
donation [2.5 pmp (1.5–4.0)] increased the total number
of kidney transplants to 39.2 pmp (34.7–42.8) (Fig. 2b).
Table 1. continued
Variable
Graft loss 5 years after transplantation
All causes 34 (12%)
Censored for patient death 14 (5%)
Recipient death 5 years after transplantation 21 (7%)
*Median (inter-quartile range).
†Data are missing from some recipients who were excluded from per-
centage calculations.
‡Donor type is stratified according to the Maastricht Categories [13].
Table 2. Indication for transplantation in 287 recipients of kidneys
donated after circulatory death in Belgium between 2000 and 2009.
Indication for transplantation n (%)
Glomerular diseases 77 (27)
Polycystic kidneys 58 (20)
Uncertain etiology 35 (12)
Tubular and interstitial diseases 30 (11)
Retransplant/Graft failure 26 (9)
Diabetes 22 (8)
Hypertensive nephroangiosclerosis 15 (5)
Congenital, rare familial, metabolic disorders 11 (4)
Renovascular and other renal vascular diseases 9 (3)
Neoplasms 3 (1)
Others (familial nephropathy) 1 (<1)
DCD, donation after circulatory death.
Figure 1 Patient and graft Kaplan–Meier survival curves until 5 years
post-transplant of all kidneys donated after circulatory death in Bel-
gium between 2000 and 2009.
Kidney transplantation of grafts donated after circulatory death in Belgium Jochmans et al.
ª 2012 The Authors
860 Transplant International ª 2012 European Society for Organ Transplantation 25 (2012) 857–866
Although Belgium reintroduced DCD kidney transplanta-
tion in 2000, the number of DCD transplants was low
until 2003, after which a steady increase occurred with
DCDs comprising up to 16% of deceased donor kidneys
in 2010. Between 2000 and 2005, only 1.5% (0.75–4.25)
of all transplanted deceased donor kidneys originated
from DCD donors. Between 2006 and 2010, this number
increased to 16% (12–16.5; P = 0.04). Table 4 shows the
evolution of kidney donation and transplantation rates.
Despite an increase in DCD donation, total deceased kid-
ney donor rates did not increase. Living donors only
slightly increased the total kidney donation rates.
Increased kidney transplants from DCDs and living
donors did not result in a significant increase of total kid-
ney transplant activity.
Evolution of kidney donation and transplantation rates
in the Netherlands since 1995
In the Netherlands, effective kidney donation rates
reached 25.0 pmp (19.9–34.9) between 1995 and 2010.
Kidney donors were equally distributed between living
donors [12.2 pmp (7.3–20.8)] and deceased donors [12.5
pmp (12.0–13.6)], with DBDs [8.1 pmp (7.4–10.2)] as
well as DCDs [4.1 pmp (2.2–5.5)] (Fig. 2c). Kidneys were
mainly transplanted from deceased donors [23.2 pmp
(22.1–24.9)], both from DBDs [14.7 pmp (13.7–19.1)]
and DCDs [7.6 pmp (3.7–10.0)]. Living donor transplants
[12.4 pmp (7.3—20.8)] increased the total number to
35.4 pmp (31.3–44.6) (Fig. 2d). Table 4 shows the evolu-
tion of kidney donation and transplantation rates. Living
donation resulted in increased kidney donation rates.
Deceased donation activity remained stable, but DBD
activity decreased significantly, whereas an exponential
increase in DCDs was observed (Table 4, Fig. 3). Kidney
transplantation rates also increased, mainly because of
increased living donations (in 2010, 57% of transplanta-
tions were with living donor kidneys). Deceased donor
kidney transplant rates remained stable, with increasing
use of DCD kidneys and decreasing transplants from
DBDs (Table 4, Fig. 3).
Discussion
This Belgian survey shows that DCD kidney transplant
programs resulted in good immediate function and excellent
Table 3. Uni- and multivariate logistic regression for the development of delayed graft function.*
Variable
Univariate (n = 287)† Multivariate (n = 203)‡
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Donor and surgical characteristics
Age (years) 1.00 (0.97–1.02) 0.73
Gender – female versus male 0.78 (0.46–1.34) 0.37
Terminal serum creatinine (mg/dl) 1.93 (0.90–4.12) 0.09
History of arterial hypertension 0.91 (0.44–1.90) 0.80
Uncontrolled versus controlled DCD 4.59 (1.77–11.96) 0.002 3.13 (0.99–9.91) 0.05
Preservation solution – UW versus HTK 0.14 (0.04–0.47) 0.001 0.19 (0.57–0.67) 0.01
Machine perfusion versus cold storage 0.66 (0.40–1.09) 0.11 0.35 (0.16–0.74) 0.01
Delayed versus immediate machine perfusion 1.44 (0.59–3.52) 0.43
Warm ischemia time (min) 1.01 (1.0–1.03) 0.10
Acirculatory time (min) 1.05 (1.01–1.10) 0.03
Cold ischemic time (h) 1.06 (1.01–1.12) 0.03 1.11 (1.32–1.19) 0.01
Anastomotic time (min) 1.00 (0.97–1.02) 0.73
Recipient characteristics
Age (years) 1.02 (1.00–1.04) 0.07
Gender – female versus male 0.65 (0.39–1.10) 0.11 0.52 (0.26–1.04) 0.06
Duration pre-transplant dialysis (mo) 1.01 (1.00–1.02) 0.09 1.02 (1.00–1.03) 0.06
Retransplant versus first transplant 1.18 (0.50–2.76) 0.71
Panel reactive antibodies (%) 1.01 (0.99–1.02) 0.58
HLA mismatches 0.73
Level 2 versus Level 1 0.73 (0.34–1.57)
Level 3 versus Level 1 0.83 (0.07–10.2)
CI, confidence interval; DCD, donation after circulatory death; HTK, histidine-tryptophan-ketoglutarate solution; UW, University of Wisconsin pres-
ervation solution.
*Multivariate model was constructed using backward stepwise regression of covariates with a univariate P < 0.15.
†Data are missing for some recipients; these were excluded case wise from multivariate analysis.
‡Hosmer-Lemeshow test of final model: v2 5.8 on 8 d.f., P = 0.67.
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medium-term outcome. Indeed, a 31% DGF incidence in
DCD kidneys is lower than commonly reported and is in
fact comparable to DGF rates observed in DBD kidneys
(13–35%) [3,4]. This low DGF rate likely results from
short cold ischemic times and the use of machine perfu-
sion. Our multivariate analysis, although limited by its ret-
rospective nature, showed that cold ischemic time and
cold storage are independent risk factors of DGF. This is
consistent with a recent Eurotransplant randomized con-
trolled trial showing that machine perfusion significantly
reduces the risk of DGF in DCD kidneys [16,17]. Of note,
16% of the kidneys in the current analysis were part of the
Eurotransplant trial. Following the report of a UK ran-
domized controlled trial that did not show a benefit of
machine perfusion [18], it has been suggested that kidneys
should be machine perfused immediately following pro-
curement until transplantation [19]. In this analysis, no
difference was observed in DGF between immediate versus
delayed perfusion. However, an effect could have remained
undetected because only a minority of kidneys underwent
delayed machine perfusion.
We observed only three PNF cases (1%), contrary to
generally higher PNF rates reported in DCD kidneys
[3,4]. Although no formal analysis on the risk factors of
PNF could be performed, the low PNF rate is likely
explained by the majority of controlled Maastricht Cate-
gory III donors, the relatively short warm ischemic and
acirculatory times, anastomotic time and cold ischemia
time, and possibly the use of machine perfusion [20]. In
addition, donors were young with excellent kidney func-
tion and only rarely suffered from hypertension.
Unfortunately, the introduction of DCD kidney trans-
plantation did not lead to a major increase in the Belgian
kidney transplant activity. There are several possible con-
tributing factors.
Firstly, despite the high number of DBDs in Belgium
there is room for improvement. Only 67% of potential
DBDs are identified and of these 10% are never reported
[21]. One strategy to improve donor identification and
referral is the Spanish model of the ‘donor facilitator’;
professionals responsible for donor identification and
evaluation, supporting intensive care personnel charged
Figure 2 Total number of effective kidney donors and transplantations per milion population in Belgium (panel a–b) and the Netherlands (panel
c–d) between 1995 and 2010. Data adapted from Eurotransplant [10,12]. LD, living donor; DBD, donation after brain death; DCD, donation after
circulatory death
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with donor maintenance, and interviewing donor families
[22]. In Belgium, donor facilitators have recently been
appointed through a national initiative, the GIFT-project
[23]. In addition, training of health-care professionals
involved in donation and transplantation and national
campaigns to increase public awareness should be pur-
sued [23].
Secondly, the full potential of controlled DCDs is not
used. As many as 26% of all ICUs deaths are potential
controlled DCD donors, but less than 4% of DCDs are
identified, indicating a real possibility to increase the
donor pool (survey Ministry of Health, L. De Pauw, per-
sonal communication). A possible explanation could be
the extreme caution and skepticism by which DCDs were
originally approached in Belgium. The initial mixed
results of international DCD programs reporting high
DGF and PNF rates [6,24–28] held the Belgian DCD pro-
grams back for another 2–3 years [29]. At the time, it
was advocated that ‘the development of a non-heart beat-
ing program is no longer acceptable if machine perfusion
and viability testing are not available’ [30]. The publica-
tion by Weber et al., showing equal long-term results for
DBD and DCD kidneys, even without machine perfusion
[7], increased confidence in DCD donation and lead to a
marked increase in DCD kidney transplants after 2003.
Meanwhile, it has also been shown that viability testing –
based on renal vascular resistances and biomarkers in the
perfusate – is not as straightforward as has always been
assumed [31–33].
Although it might be too early to distinguish the effect
of DCD programs on the overall transplant activity, there
is an increasing concern that DBDs are being recovered as
DCDs, i.e. potential donors with major, irreversible neuro-
logical injury are prematurely referred as DCDs, before
brain death occurs. Especially in the UK [34] and the
Netherlands (Figs 2 and 3, Table 4) the increase in DCDs
has been accompanied by an alarming decrease in DBDs.
The shortage of ICU resources and perhaps the erroneous
perception that DCDs and DBDs have equivalent results
may encourage physicians to refer potential donors earlier
as DCDs, even if they may progress to brain death at a
later stage. In addition, the possibility to offer withdrawal
of life support earlier could avoid unnecessary prolonged
suffering for patients and families in case of unrecoverable
neurological damage [35]. Furthermore, improved and
more aggressive neurosurgical decompressive treatments
Table 4. Evolution of kidney donors and transplants in Belgium and the Netherlands between 1995 and 2010.
1995–1999 2000–2005 2006–2010 P-value
Belgium
Kidney donors (pmp)
Total 22 (21–24) 21 (21–24) 26 (25–27) 0.01
Living donor 2 (2–3) 1 (1–2) 4 (4–5) <0.01
Deceased donor 20 (19–22) 20 (19–23) 22 (21–24) 0.30
DBD 20 (19–22) 19 (18–22) 19 (17–21) 0.62
DCD 0 (0–0) 0 (0–1) 3 (3–4) 0.01
Kidney transplants (pmp)
Total 40 (34–41) 35 (33–40) 43 (40–43) 0.10
Living donor 2 (2–3) 1 (0–3) 4 (4–5) 0.01
Deceased donor 38 (31–38) 33 (31–39) 39 (36–39) 0.21
DBD 37 (31–38) 32 (30–38) 33 (30–34) 0.57
DCD 0 (0–1) 1 (0–2) 5 (5–6) 0.01
The Netherlands
Kidney donors (pmp)
Total 19 (19–20) 25 (23–29) 37 (33–39) <0.01
Living donor 6 (6–8) 12 (11–16) 25 (20–27) <0.01
Deceased donor 14 (11–15) 13 (12–13) 12 (12–14) 0.59
DBD 13 (9–13) 8 (8–9) 7 (7–9) 0.01
DCD 1 (1–2) 5 (3–6) 5 (5–6) 0.01
Kidney transplants (pmp)
Total 31 (30–32) 35 (33–40) 49 (42–50) <0.01
Living donor 6 (6–8) 12 (11–16) 25 (20–27) <0.01
Deceased donor 25 (22–26) 24 (22–25) 23 (21–25) 0.57
DBD 23 (18–24) 14 (14–16) 14 (12–16) 0.01
DCD 2 (2–4) 9 (6–11) 10 (8–10) 0.01
DBD, donation after brain death; DCD, donation after circulatory death; pmp, per million population.
Values are presented as median (inter-quartile range).
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delay or even prevent development of brain death after
neurological disasters [35]. Although an alleged substitu-
tion of DBDs for DCDs is very difficult to prove, the pos-
sibility of it occurring is extremely worrisome because, as
a result, total deceased donor transplant activity is not
increasing. Furthermore, DCD liver transplantation results
in higher rates of biliary complications and decreased graft
survival, DCDs critically diminish the donor population
for heart transplantation, and there are fewer organs
retrieved from DCDs with a lower utilization rate. The
observation that DBD activity has continued to increase –
albeit slightly – in most European countries, except those
with established DCD programs like the Netherlands and
UK, supports a substitution phenomenon. A survey of the
Belgian Ministry of Health has shown that the potential of
DBD has decreased from 8% to 6% of ICU deaths between
2007 and 2010 (L. De Pauw, personal communication).
To effectively increase the deceased donor pool without
compromising the excellent results of transplantation,
DCD donation should ideally only concern donors that
would otherwise not progress to brain death. In this
regard, uncontrolled DCDs (Maastricht Category I and
II) represent a scarcely explored source of kidney grafts
that does not compete with DBDs. Uncontrolled DCD
donation is predominant utilized only in Spain and
France, where controlled DCD is not allowed [36].
Although graft survival of uncontrolled DCD kidneys
seems to be similar to controlled DCDs in experienced
centers, data on long-term results in large patient cohorts
are scarce [20,36–38]. Our limited experience with
uncontrolled donation has resulted in a higher DGF rate,
but equally good 5-year outcome compared with con-
trolled DCDs. Unfortunately, procurement and organ uti-
lization rates in these uncontrolled DCDs are lower than
in controlled DCD with considerably increased use of
resources and potentially demotivating donor hospitals
and procurement teams [36].
Another potential source of DCD organs are organs
donated after euthanasia. Since 2002, euthanasia is legal
in Belgium under strict conditions [39]. At the explicit
wish of the patient requesting euthanasia and after Ethical
Committee approval, organ donation can be considered.
A limited number of cases have been performed with
excellent results [40,41]. The potential of donation after
euthanasia is substantial; 335 cases of euthanasia with a
noncancerous diagnosis were performed in Belgium
between 2002 and 2007, with increasing numbers every
year [42].
Because of the high rate of deceased donation in Bel-
gium, it has long been thought that the need for living
donation was less urgent than in countries with low
deceased donation. However, this review shows that over-
all deceased donor activity has not increased significantly
over the last 15 years, whereas waiting times for a
deceased kidney have increased (median of 787 days in
2000 and 864 days in 2010). Extensive worldwide experi-
ence with living kidney donation, the safety of unilateral
nephrectomy in selected healthy living donors [43–45],
the development of minimally invasive surgery, and the
superior results of living versus deceased donor kidney
transplantation [46], support the further development of
living donation in Belgium. Matching the living donor
activity to that in the Netherlands or in the United States
would double the total transplant activity in Belgium.
In conclusion, DCD kidney transplantation in Belgium
results in good immediate function and excellent med-
ium-term outcome. However, until now DCD programs
have not resulted in an increase of total deceased donor
kidney transplant activity, possibly related to a substitu-
tion of DCD to DBD donors. To increase its kidney
Figure 3 Evolution of effective deceased kidney donors (panel a)
and transplants (panel b) per milion population in Belgium and the
Netherlands between 1995 and 2010. Data adapted from Eurotrans-
plant [10]. DBD, donation after brain death; DCD, donation after
circulatory death.
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transplant activity, Belgium should (i) improve the identi-
fication and reporting of all DBD donors with support of
appointed donor facilitators; (ii) pursue the development
of controlled DCD donation while avoiding premature
referral of potential donors who may progress to brain
death; (iii) explore uncontrolled DCD donation; and (iv)
increase living donation.
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